Deutsche downgrades Merck ahead of Keytruda 2028 expiration
Deutsche Bank analyst James Shin downgraded Merck (MRK) to Hold from Buy with a price target of $105, down from $128. The firm believes the ...
Gilead upped on HIV franchise; Merck downgraded on Keytruda LoE at Deutsche Bank
Gilead (GILD) stock won an upgrade from Deutsche Bank on HIV treatment boost, while Merck (MRK) stock received a downgrade on ...
The Vistria Group Announces the Appointment of Healthcare Pioneer Dr. Tony Coles as Senior Advisor
The Vistria Group, LP ("Vistria"), a middle market private investment firm that seeks to deliver both superior financial returns and meaningful impact, today announced that Dr. Tony Coles, MPH will ...
BioSpace1d
5 Pharma Powerhouses Facing Massive Patent Cliffs—And What They’re Doing About It
Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...
Hegseth Calls for 8 Percent Annual Defense Cut
Defense Secretary Pete Hegseth has ordered senior military and Defense Department officials to draw up plans to cut 8 percent ...
Medincell Launches a Global Offering for Approximately 10% of Its Share Capital
The Global Offering, for approximately 10% of the Company’s share capital, is aimed at international institutional investors, via a Private Placement through an accelerated book-building process. The ...
MM&M6d
Pharma brands are struggling to keep the attention of digitally savvy HCPs
It’s critical to understand what a digitally savvy HCP is in 2025 and what’s impeding pharma's communications with this ...
Genmab: Positive 2025 Outlook, Johnson & Johnson's Decision Coming Soon
Genmab's Q4 2024 results impress with $897.4M revenue and 29% growth. GMAB's balance sheet is strong with nearly $3 billion ...
Evolus's SWOT analysis: FDA nod for filler boosts stock outlook
Evolus Inc . (NASDAQ:EOLS), a company specializing in aesthetic products with a market capitalization of $933 million, has recently made significant strides in expanding its product portfolio and ...
Is AbbVie Stock a Buy Now?
AbbVie (NYSE: ABBV) closed out a pivotal 2024 with an excellent fourth-quarter earnings report. For the period ended Dec. 31, ...
Dr. Mehmet Oz holds millions from companies that he'd wield power over if confirmed, report shows
WASHINGTON (AP) — The wealth of Dr. Mehmet Oz, the celebrity heart surgeon nominated by President Donald Trump to lead the ...
The Motley Fool5d
Is AbbVie Stock a Buy Now?
AbbVie reported better-than-expected fourth-quarter earnings. Strong demand for the company's Skyrizi and Rinvoq autoimmune therapeutics has helped offset the decline in Humira sales since losing ...